突变状态对自噬和免疫反应的影响：未被关注的靶点。
Mutation Status Impact on Autophagy and Immune Response: Unheralded Target.
作者信息
Morand Susan, Stanbery Laura, Walter Adam, Rocconi Rodney P, Nemunaitis John
机构信息
Department of Internal Medicine, University of Toledo, Toledo, OH, USA.
Gradalis, Inc, Carrollton, TX, USA.
出版信息
JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077. doi: 10.1093/jncics/pkaa077. eCollection 2020 Dec.
Abstract
BRCA1 and possibly BRCA2 proteins may relate to the regulation of autophagy. Autophagy plays a key role in immune response from both a tumor and immune effector cell standpoint. In cells with mutations, increased autophagy leads to elevated expression of major histocompatibility complex class II but may cause subclonal neoantigen presentation, which may impair the immune response related to clonal neoantigen visibility. We review evidence of BRCA1/2 regulation of autophagy, immune response, and antigen presentation.
摘要
BRCA1 以及可能的 BRCA2 蛋白可能与自噬的调节有关。从肿瘤和免疫效应细胞的角度来看，自噬在免疫反应中起着关键作用。在存在突变的细胞中，自噬增加会导致主要组织相容性复合体 II 类分子的表达升高，但可能会引起亚克隆新抗原呈递，这可能会损害与克隆新抗原可见性相关的免疫反应。我们综述了 BRCA1/2 对自噬、免疫反应和抗原呈递调节的相关证据。
相似文献
1
Mutation Status Impact on Autophagy and Immune Response: Unheralded Target.突变状态对自噬和免疫反应的影响：未被关注的靶点。
JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077. doi: 10.1093/jncics/pkaa077. eCollection 2020 Dec.
2
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.PARP抑制剂AZD2281（奥拉帕尼）可诱导BRCA1和BRCA2突变的乳腺癌细胞发生自噬/线粒体自噬。
Int J Oncol. 2015 Jul;47(1):262-8. doi: 10.3892/ijo.2015.3003. Epub 2015 May 12.
3
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.日本原位导管癌女性中的BRCA1/BRCA2基因突变
Mol Genet Genomic Med. 2019 Mar;7(3):e493. doi: 10.1002/mgg3.493. Epub 2019 Jan 16.
4
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.BRCA1/2基因突变状态与高级别浆液性卵巢癌新抗原负荷、肿瘤浸润淋巴细胞数量及PD-1/PD-L1表达的相关性及预后意义
Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.
5
Assessment of ovarian reserve and reproductive outcomes in or mutation carriers.评估 OR 突变携带者的卵巢储备和生殖结局。
Int J Gynecol Cancer. 2020 Jan;30(1):83-88. doi: 10.1136/ijgc-2019-000626. Epub 2019 Nov 27.
6
BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.黎巴嫩阿拉伯族裔患遗传性高危乳腺癌女性中的BRCA1和BRCA2基因突变
Oncologist. 2015 Apr;20(4):357-64. doi: 10.1634/theoncologist.2014-0364. Epub 2015 Mar 16.
7
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.乳腺癌和卵巢癌中 BRCA 的表达与突变：生物信息学分析证据。
Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.
8
The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.BRCA1 和 BRCA2 突变与前列腺癌风险、频率和死亡率的关联：一项荟萃分析。
Prostate. 2019 Jun;79(8):880-895. doi: 10.1002/pros.23795. Epub 2019 Mar 22.
9
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.在与BRCA1和BRCA2种系突变相关的卵巢癌中，p53蛋白的积累很常见。
J Clin Pathol. 1999 May;52(5):372-5. doi: 10.1136/jcp.52.5.372.
10
Autophagy protein ATG5 regulates CD36 expression and anti-tumor MHC class II antigen presentation in dendritic cells.自噬蛋白 ATG5 调节树突状细胞中 CD36 的表达和抗肿瘤 MHC Ⅱ类抗原呈递。
Autophagy. 2019 Dec;15(12):2091-2106. doi: 10.1080/15548627.2019.1596493. Epub 2019 Apr 6.
引用本文的文献
1
Tumor-infiltrating lymphocytes are the key determinants of pathological features associated with pathogenic variants in high-grade serous ovarian carcinoma.肿瘤浸润淋巴细胞是与高级别浆液性卵巢癌致病变异相关的病理特征的关键决定因素。
Front Med (Lausanne). 2025 Jun 3;12:1555883. doi: 10.3389/fmed.2025.1555883. eCollection 2025.
2
Components of the Endosome-Lysosome Vesicular Machinery as Drivers of the Metastatic Cascade in Prostate Cancer.作为前列腺癌转移级联驱动因素的内体-溶酶体囊泡机制的组成部分
Cancers (Basel). 2024 Dec 26;17(1):43. doi: 10.3390/cancers17010043.
3
Complex Interplay between DNA Damage and Autophagy in Disease and Therapy.DNA 损伤与自噬在疾病与治疗中的复杂相互作用。
Biomolecules. 2024 Jul 29;14(8):922. doi: 10.3390/biom14080922.
4
Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer.使用同源重组 proficient 分子谱作为卵巢癌治疗靶点生物标志物的原理。
Oncol Rev. 2023 Sep 20;17:11471. doi: 10.3389/or.2023.11471. eCollection 2023.
5
Identification of SNPs Related to Resistance in Chickens Using RNA-Seq and Integrated Bioinformatics Approach.利用 RNA-Seq 和综合生物信息学方法鉴定与鸡抗药性相关的 SNPs。
Genes (Basel). 2023 Jun 17;14(6):1283. doi: 10.3390/genes14061283.
6
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.BRCA1/2 突变携带者的正常乳腺组织中免疫细胞增多。
Breast Cancer Res Treat. 2023 Jan;197(2):277-285. doi: 10.1007/s10549-022-06786-y. Epub 2022 Nov 16.
7
Identification and Validation of Autophagy-Related Genes in Primary Ovarian Insufficiency by Gene Expression Profile and Bioinformatic Analysis.基于基因表达谱和生物信息学分析鉴定原发性卵巢功能不全的自噬相关基因。
Anal Cell Pathol (Amst). 2022 Jul 4;2022:9042380. doi: 10.1155/2022/9042380. eCollection 2022.
8
-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms.- 突变型胰腺癌：从发现到新型治疗模式
Cancers (Basel). 2022 May 16;14(10):2453. doi: 10.3390/cancers14102453.
9
Targeting DNA repair pathways to overcome cancer drug resistance.靶向DNA修复途径以克服癌症耐药性。
Cancer Drug Resist. 2021;4(4):837-841. doi: 10.20517/cdr.2021.80. Epub 2021 Aug 19.
10
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.Gemogenovatucel-T（Vigil）在复发性卵巢癌中的长期随访：生存情况及免疫反应的分子信号
Vaccines (Basel). 2021 Aug 12;9(8):894. doi: 10.3390/vaccines9080894.
本文引用的文献
1
Exosomes and autophagy: rekindling the vesicular waste hypothesis.外泌体与自噬：重拾囊泡废物假说
J Cell Commun Signal. 2019 Dec;13(4):443-450. doi: 10.1007/s12079-019-00524-8. Epub 2019 Jun 6.
2
Genomic correlates of response to immune checkpoint blockade.免疫检查点阻断治疗反应的基因组相关性。
Nat Med. 2019 Mar;25(3):389-402. doi: 10.1038/s41591-019-0382-x. Epub 2019 Mar 6.
3
The immune system profoundly restricts intratumor genetic heterogeneity.免疫系统深刻地限制了肿瘤内遗传异质性。
Sci Immunol. 2018 Nov 23;3(29). doi: 10.1126/sciimmunol.aat1435.
4
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.肿瘤细胞 MHC-II 表达在癌症中的生物学后果
Clin Cancer Res. 2019 Apr 15;25(8):2392-2402. doi: 10.1158/1078-0432.CCR-18-3200. Epub 2018 Nov 21.
5
The multifaceted role of autophagy in cancer and the microenvironment.自噬在癌症和微环境中的多效性作用。
Med Res Rev. 2019 Mar;39(2):517-560. doi: 10.1002/med.21531. Epub 2018 Oct 9.
6
The interplay between exosomes and autophagy - partners in crime.外泌体与自噬的相互作用——共犯关系。
J Cell Sci. 2018 Aug 3;131(15):jcs215210. doi: 10.1242/jcs.215210.
7
Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.敲低 BRCA2 增强卵巢癌细胞对顺铂和顺铂诱导自噬的敏感性。
Endocr Relat Cancer. 2018 Jan;25(1):69-82. doi: 10.1530/ERC-17-0261. Epub 2017 Oct 24.
8
The crosstalk between autophagic and endo-/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses.自噬与内体/外体途径在 MHC 呈递相关抗原加工中的串扰及其在抗肿瘤 T 细胞免疫应答中的作用。
J Hematol Oncol. 2017 Oct 23;10(1):165. doi: 10.1186/s13045-017-0534-8.
9
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.用于癌症免疫治疗的PD-1和PD-L1检查点信号抑制：机制、联合应用及临床结果
Front Pharmacol. 2017 Aug 23;8:561. doi: 10.3389/fphar.2017.00561. eCollection 2017.
10
The roles of subcellularly located EGFR in autophagy.亚细胞定位的表皮生长因子受体（EGFR）在自噬中的作用。
Cell Signal. 2017 Jul;35:223-230. doi: 10.1016/j.cellsig.2017.04.012. Epub 2017 Apr 18.
Zotero 插件